And very good afternoon, Thank Taylor. much, everyone. you
some be my here it's of pleasure discuss all, of recent operating First highlights. our to today to
XX across the surpassed years treatment ago. than after treatments achieving we XXX,XXX cumulative XXX,XXX milestone CytoSorb less countries three First,
of cumulative the worldwide. of the XXXX, XXX,XXX than first treatments number was of more quarter end As the
November milestone second is second on Data initiate trial the shortly triggered to the achieved be in of after Next, achieving milestone pivotal months. of XXXX. that its first and Board schedule in enrolled few a XX the next completed review expected STAR-T of enrolled This patients Monitoring patients Safety and Independent XX
was the from The quarter from exceeded sales that with on product a a million, typically five years quarter strong ago XXXX of adjusted of representing growth QX of first a $X.X total the in year solid last first core core including past time revenue million, and year both a QX. This quarter sales sequential was basis. currency first $X.X
ended cash million. We with XXXX healthy also QX a balance $XX.X of
Next, next Al Kraus, of will his him the Michael his Bator, term leadership our the month of results pending board meeting chairman, June. the of after as board the announced chairman, end annual upcoming with succeed company. at retirement our current XX years in director, board
a Next, publication underscoring responsible endotoxin we reduce CytoSorb inflammation half human recently the sepsis of caused hyper a called in critical care in definitively for study. cytokine that storm highlighted in well-controlled a systemic key of toxin inflammation is by cases during key to power
inflammation to conferences research the the of And in XXXX, finally, and Intensive at and as shock, highly CytoSorb influential International ARDS. we premier using Medicine such cytokine and sepsis, most of treat ISICEM one storm Medicine, hosted highlighting diseases attended critical Care a and or the Emergency successful symposium care world, data Symposium in and
objectives. in beginning on three discussed we the the are the in of at As we major shareholder XXXX, year, focused letter
Canadian the US opening markets. is and first The
expenses. growth, second tight return to The a is a third a over burn reduction is and of cash with sales our control
limited will we these sake keep For to our of remarks call, prepared each three the of today's areas.
on to questions Q&A session. in However, the any subject happy take we're
and color DrugSorb-ATR. Canadian on to First, a me the more US little markets objective with open allow provide our to
Canadian many you to open aware, and efforts US STAR-T core of the and clinical remains the of the vehicle our expected DrugSorb-ATR As markets. are and focus
of FDA cardiothoracic can We've in breakthrough risk that two patients bleeding blood for device received perioperative surgery. designation thinning DrugSorb-ATR to undergoing the increase remove medications
third now is has our brisk achievement the trial. recently Since enrollment internal and in of the the with STAR-T the centers. Enrollment been announcing enrolled, last Canadian enthusiasm patients study by study are own centers. outpaced all continues has enrolling high the by XX trial of US contribution projections. to all enroll sites for there's and well. Nearly And strong trial both recently
the before by pushing to FDA complete with trigger If summer We're expected Health as end submissions and positive, top of year. this to enrollment would US Canada. data the and the STAR-T regulatory soon possible line as both
at to and responsibilities team, to parallel meet that the on our submissions interdepartmental strategy for regulatory to strengthening US includes Health driving this FDA regulatory executing the clinical and regulatory Canada, In alignment program, planning both and regulatory stage and timelines. also objectives future we're our
their can coverage or Coverage that Emerging such Transitional proposal Finally, devices, Technologies, four DrugSorb-ATR. relevant update breakthrough we're on CMS years provide an of TCET, approved on as waiting of to from
me analysis forego press in the achieving the color. in give on patients we the milestone the deciding release the Although rationale some the of again last additional of recent patients discussed XX in earnings XX STAR-T trial, interim to to call, second and allow enrollment
To that analysis pace to XX formal important interim to of a opportunity the elect on As the if trial be option analysis was first this understand STAR-T slow enrollment intent important or of provide was to us rapid expected of to interim forego clarify this enrollment stop to decision, led delayed. patients. fully the to a it's the discussed an early, original recently,
likely is that adjudicated the be the that completed are locked of efforts analysis. other believe stopped this making interim decision, considerations important emphasize study underlying our because analysis will value. and projection that current suggests remains fully formal And information data it's analysis trial interim our brisk, pace Accordingly, We way, now that, been fully the enrolled by blinded. or on and early, final completed. an be a are monitored, the fully no have we by the time data, STAR-T trial there also that, clean the focusing is that no would of of cannot enrollment requires to However, and
The to next we Board second which is milestone completed first Monitoring in the the be expect independent Data XX few Safety patients evaluation safety the for STAR-T after next months.
As previously of the the the after safety continue XX to recommendation was without evaluation disclosed, planned DSMB to as patients modification. study first
return quarterly an product we second core to year-over-year, to encouraging is of quarter sales to quarter the switch let's XXXX, of is compared sequential the growth. believe of XXXX Now growth in sales which the product which a growth terms fourth sales for witnessed We in milestone key X% an XXXX and first sign.
trend strong most on markets of countries, We're excellent customer an data, engagement, although improvement workers staffing healthcare our scientific in issue. in clinical and continues hospital remain our seeing core and feedback to a recent
do example, accounts those our product of to as XX%. surgical XX% more surgery. cardiac adding of to COVID-XX of beds for all ICU translate total non-COVID patients to COVID-XX higher by are expected fallen to which Meanwhile, more under which recover where ICU the ICU conditions admit These in revenue, number drivers has This full operations need the ICU admissions roughly operating is and for to patients into Germany, ICUs our patients prospect that ability XX% released, ICU, will to for raising significantly, reporting such business. to the dropped normal restrictions than the capacity. about now In the is reserved be the have to
XX% networks accounts And by German agreements. number growth the in initiatives, on XXXX XXXX supplier based of of among many private in our our we've hospital to increased compared also preferred
XXXX, quarter full now production mode is brisk. demand we the meeting CytoSorb replenishing of production, first the Finally, our finished of manufacturing facility, new demand was goods with ramping the in Working inventory. and down in of are for inventory, which currently goal out
and I'd With that, turn to our to Kathy discuss to now third objective. over it Kathy? financials key like our
